Schwieriges und schweres, therapierefraktäres Asthma bronchiale beim Erwachsenen

Schlüsselwörter

schweres Asthma bronchiale - refraktäres Asthma bronchiale - Phänotypen

Keywords

severe asthma - uncontrolled asthma - phenotypes

• Literatur

• 1 American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162: 2341-2351
• 2 Antonicelli L, Bucca C, Neri M et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23: 723-729
• 3 Barnes PJ, Dweik RA, Gelb AF et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010; 138: 682-692
• 4 Bel EH, Sousa A, Fleming L et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66: 910-917
• 5 Bousquet J, Khaltaev N, Cruz AA et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86) 8-160
• 6 Bousquet J, Mantzouranis E, Cruz AA et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926-938
• 7 Buhl R, Berdel D, Criee CP et al. Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie 2006; 60: 139-177
• 8 Bundesärztekammer (BÄK) KBKAdWMFA. Nationale Versorgungs Leitlinie Asthma – Langfassung. . 2. Aufl. Version 1.3.2 2011. http://www.asthma-versorgungsleitlinien.de/2011
• 9 Chung KF, Godard P, Adelroth E et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999; 13: 1198-1208
• 10 Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098
• 11 Denning DW, O'Driscoll BR, Powell G et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179: 11-18
• 12 European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22: 470-477
• 13 GINA Report. Global Strategy for Asthma Management and Prevention. 2010 www.ginasthma.org
• 14 Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984
• 15 Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-224
• 16 Harding SM, Guzzo MR, Richter JE. The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms. Am J Respir Crit Care Med 2000; 162: 34-39
• 17 Kerstjens HA, Disse B, Schroder-Babo W et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128: 308-314
• 18 Kiljander TO, Junghard O, Beckman O et al. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2010; 181: 1042-1048
• 19 Kowalski ML, Cieslak M, Perez-Novo CA et al. Clinical and immunological determinants of severe/refractory asthma (SRA): association with staphylococcal superantigen-specific IgE antibodies. Allergy 2011; 66: 32-38
• 20 Luks VP, Vandemheen KL, Aaron SD. Confirmation of asthma in an era of overdiagnosis. Eur Respir J 2010; 36: 255-260
• 21 Mackay D, Haw S, Ayres JG et al. Smoke-free legislation and hospitalizations for childhood asthma. N Engl J Med 2010; 363: 1139-1145
• 22 Mastronarde JG, Anthonisen NR, Castro M et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009; 360: 1487-1499
• 23 Moore WC, Meyers DA, Wenzel SE et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315-323
• 24 Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993
• 25 Peters SP, Kunselman SJ, Icitovic N et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363: 1715-1726
• 26 Robinson DS, Campbell DA, Durham SR et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22: 478-483
• 27 Taube C, Buhl R. Hilft die Phänotypisierung des Asthmas bei der Differentialtherapie?. Dtsch Med Wochenschr 2010; 135: 468-473
• 28 The American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175: 235-242
• 29 Williams LK, Joseph CL, Peterson EL et al. Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol 2007; 120: 1153-1159